Showing results (111-120 of 186) with videos related to

Sort By:
Pageof 19
Blood Advances|October 14, 2021
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphomaVictor A Chow, Ryan D Cassaday, Theodore A Gooley, et al.
Blood|September 30, 2009
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndromeJohn M Pagel, Theodore A Gooley, Joseph Rajendran, et al.
Haematologica|October 5, 2019
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasiaPhuong Vo, Ted A Gooley, Joseph G Rajendran, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 12, 2021
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing AnalysisStephen D Smith, Paolo Lopedote, Yazeed Samara, et al.
Blood Advances|June 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomasChristina Poh, Jenna M Voutsinas, Mazyar Shadman, et al.
Cancer Research|June 2, 2017
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell LymphomasShyril O'Steen, Damian J Green, Ajay K Gopal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin LymphomasAjay K Gopal, Ronald Levy, Roch Houot, et al.
Plos One|March 19, 2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft modelsSofia H L Frost, Shani L Frayo, Brian W Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term SurvivorsJohnnie J Orozco, Phuong T Vo, Ted A Gooley, et al.
Frontiers in Immunology|August 19, 2022
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung CancerDavid S Hong, Ajay K Gopal, Alexander N Shoushtari, et al.
Pageof 19